563 related articles for article (PubMed ID: 19560902)
1. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005.
Karlowsky JA; Lagacé-Wiens PR; Low DE; Zhanel GG
Int J Antimicrob Agents; 2009 Oct; 34(4):375-9. PubMed ID: 19560902
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic use among children in British Columbia, Canada.
Marra F; Patrick DM; Chong M; Bowie WR
J Antimicrob Chemother; 2006 Oct; 58(4):830-9. PubMed ID: 16921182
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of bacterial resistance to macrolides.
Halpern MT; Schmier JK; Snyder LM; Asche C; Sarocco PW; Lavin B; Nieman R; Mandell LA
J Antimicrob Chemother; 2005 May; 55(5):748-57. PubMed ID: 15772147
[TBL] [Abstract][Full Text] [Related]
5. Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.
Mason EO; Wald ER; Bradley JS; Barson WJ; Kaplan SL;
Pediatr Infect Dis J; 2003 Jul; 22(7):623-7. PubMed ID: 12867838
[TBL] [Abstract][Full Text] [Related]
6. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006.
Adam HJ; Hoban DJ; Gin AS; Zhanel GG
Int J Antimicrob Agents; 2009 Jul; 34(1):82-5. PubMed ID: 19342204
[TBL] [Abstract][Full Text] [Related]
7. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae.
Bergman M; Huikko S; Huovinen P; Paakkari P; Seppälä H;
Antimicrob Agents Chemother; 2006 Nov; 50(11):3646-50. PubMed ID: 16940064
[TBL] [Abstract][Full Text] [Related]
8. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
[TBL] [Abstract][Full Text] [Related]
9. A comparison of antibiotic use in children between Canada and Denmark.
Marra F; Monnet DL; Patrick DM; Chong M; Brandt CT; Winters M; Kaltoft MS; Tyrrell GJ; Lovgren M; Bowie WR
Ann Pharmacother; 2007 Apr; 41(4):659-66. PubMed ID: 17374628
[TBL] [Abstract][Full Text] [Related]
10. Macrolide resistance rates in respiratory pathogens in Slovenia following reduced macrolide use.
Cizman M; Beović B; Seme K; Paragi M; Strumbelj I; Müller-Premru M; Cad-Pecar S; Pokorn M
Int J Antimicrob Agents; 2006 Dec; 28(6):537-42. PubMed ID: 17101264
[TBL] [Abstract][Full Text] [Related]
11. Macrolide and ketolide resistance with Streptococcus pneumoniae.
Doern GV
Med Clin North Am; 2006 Nov; 90(6):1109-24. PubMed ID: 17116439
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF).
Tazumi A; Maeda Y; Goldsmith CE; Coulter WA; Mason C; Millar BC; McCalmont M; Rendall J; Elborn JS; Matsuda M; Moore JE
J Antimicrob Chemother; 2009 Sep; 64(3):501-6. PubMed ID: 19584106
[TBL] [Abstract][Full Text] [Related]
13. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003.
Hicks LA; Chien YW; Taylor TH; Haber M; Klugman KP;
Clin Infect Dis; 2011 Oct; 53(7):631-9. PubMed ID: 21890767
[TBL] [Abstract][Full Text] [Related]
14. [Macrolide antibiotic resistance rates and phenotypes of group A beta hemolytic streptococci isolated between the years 1999-2000 and 2001-2002].
Senses Z; Baysallar M; Gür D; Doğanci L
Mikrobiyol Bul; 2003 Oct; 37(4):225-34. PubMed ID: 14748258
[TBL] [Abstract][Full Text] [Related]
15. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
Chen DK; McGeer A; de Azavedo JC; Low DE
N Engl J Med; 1999 Jul; 341(4):233-9. PubMed ID: 10413735
[TBL] [Abstract][Full Text] [Related]
16. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001.
Bergman M; Huikko S; Pihlajamäki M; Laippala P; Palva E; Huovinen P; Seppälä H;
Clin Infect Dis; 2004 May; 38(9):1251-6. PubMed ID: 15127336
[TBL] [Abstract][Full Text] [Related]
17. Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.
Schentag JJ; Klugman KP; Yu VL; Adelman MH; Wilton GJ; Chiou CC; Patel M; Lavin B; Paladino JA
Int J Antimicrob Agents; 2007 Sep; 30(3):264-9. PubMed ID: 17587549
[TBL] [Abstract][Full Text] [Related]
18. The association between antibiotic use in the community and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in Bedouin children.
Greenberg D; Givon-Lavi N; Sharf AZ; Vardy D; Dagan R
Pediatr Infect Dis J; 2008 Sep; 27(9):776-82. PubMed ID: 18645545
[TBL] [Abstract][Full Text] [Related]
19. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.
Pihlajamäki M; Kotilainen P; Kaurila T; Klaukka T; Palva E; Huovinen P;
Clin Infect Dis; 2001 Aug; 33(4):483-8. PubMed ID: 11462184
[TBL] [Abstract][Full Text] [Related]
20. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment.
Gay K; Baughman W; Miller Y; Jackson D; Whitney CG; Schuchat A; Farley MM; Tenover F; Stephens DS
J Infect Dis; 2000 Nov; 182(5):1417-24. PubMed ID: 11023465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
